Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New vaccine aims to better protect blood cancer survivors from COVID-19

NCT ID NCT04977024

First seen Feb 11, 2026 · Last updated May 23, 2026 · Updated 16 times

Summary

This study tests a new COVID-19 vaccine (GEO-CM04S1) in 63 adults with blood cancers like leukemia or lymphoma who have had a stem cell transplant or cell therapy. The goal is to see if this vaccine triggers a stronger immune response than standard mRNA vaccines. Participants will receive two shots and be monitored for side effects and antibody levels.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LEUKEMIA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Atrium Health Wake Forest Baptist

    Winston-Salem, North Carolina, 27157, United States

  • City of Hope Medical Center

    Duarte, California, 91010, United States

  • Fred Hutchinson Cancer Center

    Seattle, Washington, 98109, United States

  • Johns Hopkins University

    Baltimore, Maryland, 21205, United States

  • SUNY-Stony Brook

    Stony Brook, New York, 11794, United States

  • U Mass Chan Medical School

    Worcester, Massachusetts, 01655, United States

Conditions

Explore the condition pages connected to this study.